PPAT

Across TCGA pan-cancer cohorts, PPAT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PPAT data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PPAT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PPAT expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.

UCEC, CCRCC, and HNSC are the cancer types where PPAT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	III,IV	1.000	0.301	.022	16	view →
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	16	view →
HNSC	DFS	Median	III,IV	0.723	0.500	.013	12	view →
LUAD	OS	Tertile	All	0.657	0.894	.013	10	view →
LSCC	OS	Tertile	II,III,IV	0.910	0.641	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PPAT–UCEC (DFS)

Open the UCEC breakdown →